CompletedNot Applicable

Real-world Data Analysis of REN Treatment in Adolescence With Migraine

United States, Israel1,629 participantsStarted 2021-01-01

Plain-language summary

This is a Post-marketing study investigating the safety and efficacy of the REN device (Nerivio by Theranica, Israel) in adolescents with migraine. Data analysis concerning the REN treatment efficacy in terms of pain and functional disability as a standalone treatment or in combination with other medications will be performed.

Who can participate

Age range12 Years – 18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. \- Age between 12-18 years
✓. \- REN user across the United States who created Nerivio account on January 1st, 2021 or later.
✓. \- Had at least two evaluable treatments with the Nerivio device

What they're measuring

Consistent Pain Relief at 2 Hours Post-treatment

Timeframe: 2 hours post treatment, up to 16 months from the 1st treatment

Trial details

NCT IDNCT05443659

SponsorTheranica

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2022-05-31

Results submitted2025-08-17

View on ClinicalTrials.gov More Migraine in Adolescence trials